Literature DB >> 1786127

Supratentorial masses: stereotactic or freehand biopsy?

T Lee1, B G Kenny, E R Hitchock, P J Teddy, H Palividas, W Harkness, C H Meyer.   

Abstract

CT-guided stereotactic biopsy is now an accepted method of tissue sampling in intracranial mass lesions but many surgeons still practise freehand burrhole biopsy. This study compares two groups of patients who had either stereotactically guided (n = 153) or freehand (n = 217) biopsy. Stereotactic biopsy has a lower incidence of both mortality (2.6%) and morbidity (1.3%) than freehand (7.8 and 7.8%) while diagnostic accuracy is 92.1 and 64.9%, respectively. The success rate for stereotactic biopsy is independent of the size and depth of the lesion while freehand biopsy is most successful for large, superficial lesions but its success never exceeds 88%. The stereotactic technique is superior to the freehand for all intracranial biopsies regardless of size or site.

Entities:  

Mesh:

Year:  1991        PMID: 1786127     DOI: 10.3109/02688699109002859

Source DB:  PubMed          Journal:  Br J Neurosurg        ISSN: 0268-8697            Impact factor:   1.596


  4 in total

Review 1.  Minimally invasive surgery. Neurosurgery.

Authors:  D G Thomas; N D Kitchen
Journal:  BMJ       Date:  1994-01-08

2.  The value of per-operative smear examination during stereotactic biopsy.

Authors:  N D Kitchen; R Bradford; J E McLaughlin
Journal:  Acta Neurochir (Wien)       Date:  1993       Impact factor: 2.216

3.  Computed tomography-guided stereotactic biopsy of intracranial lesions in pediatric patients.

Authors:  Ali Meshkini; Sohrab Shahzadi; Alireza Zali; Khosro Parsa; Aimaz Afrough; Amir Hamdi
Journal:  Childs Nerv Syst       Date:  2011-07-27       Impact factor: 1.475

4.  Surgery for primary supratentorial brain tumors in the United States, 1988 to 2000: the effect of provider caseload and centralization of care.

Authors:  Fred G Barker; William T Curry; Bob S Carter
Journal:  Neuro Oncol       Date:  2005-01       Impact factor: 12.300

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.